Mini-Laser (780 nm x 10 mW) with 1.2 m USB-cable

In 2008, a groundbreaking pilot study introduced low-level laser therapy (LLLT) – also known as photobiomodulation (PBM) – as a non-invasive treatment for Age-Related Macular Degeneration (AMD). The study evaluated LLLT at a 780 nm wavelength at 7.5 mW strength, administering for forty seconds at a 1 cm distance from the eye on four occasions over two weeks. Results demonstrated: * Improved Vision: Significant improvements in best-corrected visual acuity (BCVA) were recorded four weeks after the start of the study. * Reduced Signs & Symptoms: Decreases in drusen, macular edema, retinal bleeding and pigment accumulations. * No Side Effects: The therapy showed no adverse or morphological tissue damage. * Long Term Benefit: The visual benefits were maintained up to 36 months after conclusion of the study, despite no further treatments being administered. Since these initial findings, the technology has evolved significantly. Modern PBM treatments are now widely explored in clinical practices and trials (such as the LIGHTSITE II and III trials) for early and dry AMD. The therapy mainly works by using near-infrared light to stimulate mitochondrial energy production (ATP), thus reducing oxidative stress in retinal cells.